KROS Stock Price, Keros Therapeutics Inc Quote, Chart

Market Summary

USD58.20-0.42

Delayedas of 30 Apr 2024, 12:02 pm

-0.72%

KROS Stock Price

View Fullscreen

KROS RSI Chart

KROS Valuation

Market Cap

2.1B

Price/Earnings (Trailing)

-13.79

Price/Sales (Trailing)

1.0K

EV/EBITDA

-11.68

Price/Free Cashflow

-16.61

KROS Price/Sales (Trailing)

KROS Profitability

EBT Margin

-4361.62%

Return on Equity

-46.05%

Return on Assets

-41.35%

Free Cashflow Yield

-6.02%

KROS Fundamentals

KROS Revenue

Revenue (TTM)

2.4M

KROS Earnings

Earnings (TTM)

-153.0M

Earnings Growth (Yr)

-35.42%

Earnings Growth (Qtr)

-2.04%

Breaking Down KROS Revenue

52 Week Range

30.5759.67

(Low)(High)

Last 7 days

5.1%

Last 30 days

-11.5%

Last 90 days

4.1%

Trailing 12 Months

32.2%

How does KROS drawdown profile look like?

KROS Financial Health

Current Ratio

14.25

KROS Investor Care

Shares Dilution (1Y)

8.77%

Diluted EPS (TTM)

-5.2

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	0	0
2022	0	0	0	0
2021	0	13.4M	16.7M	20.1M
2019	10.0M	10.0M	10.0M	10.0M
2018	0	0	0	10.0M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Keros Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Nov 04, 2023	regnante keith	sold	-1,811,600	45.29	-40,000	chief financial officer
Nov 04, 2023	regnante keith	acquired	640,000	16.00	40,000	chief financial officer
Jun 09, 2023	regnante keith	sold	-908,367	45.4184	-20,000	chief financial officer
Jun 09, 2023	regnante keith	acquired	320,000	16.00	20,000	chief financial officer
Jun 08, 2023	regnante keith	acquired	320,000	16.00	20,000	chief financial officer
Jun 08, 2023	regnante keith	sold	-955,872	47.7936	-20,000	chief financial officer
Apr 08, 2023	seehra jasbir	acquired	1,920	0.48	4,000	chief executive officer
Nov 29, 2022	kariv tomer	sold	-0.7176	0.0001	-7,176	-
Nov 29, 2022	nussbaum ran	sold	-0.7176	0.0001	-7,176	-
Nov 29, 2022	pontifax management 4 g.p. (2015) ltd.	sold	-0.7176	0.0001	-7,176	-

Which funds bought or sold KROS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	Bank of New York Mellon Corp	added	5.43	2,838,220	6,595,700	-%
Apr 25, 2024	Lindbrook Capital, LLC	unchanged	-	2,353	5,892	-%
Apr 25, 2024	Zurcher Kantonalbank (Zurich Cantonalbank)	added	9.78	101,282	223,624	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	sold off	-100	-38,000	-	-%
Apr 25, 2024	WCM INVESTMENT MANAGEMENT, LLC	reduced	-24.33	1,398,430	7,747,390	0.02%
Apr 24, 2024	DekaBank Deutsche Girozentrale	unchanged	-	178,000	488,000	-%
Apr 23, 2024	BFSG, LLC	sold off	-100	-7,952	-	-%
Apr 23, 2024	AMALGAMATED BANK	reduced	-72.23	-67,000	57,000	-%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	93,654	472,548	-%
Apr 18, 2024	EDBI Pte Ltd	unchanged	-	267,176	668,951	0.75%

Are Funds Buying or Selling KROS?

Are funds buying KROS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own KROS

No. of Funds

Unveiling Keros Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	alkeon capital management llc	5.0%	1,498,907	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Jan 26, 2024	blackrock inc.	6.8%	2,036,788	SC 13G/A
Dec 13, 2023	orbimed advisors llc	4.2%	1,268,734	SC 13D/A
Feb 14, 2023	deep track capital, lp	0%	0	SC 13G/A
Feb 13, 2023	alkeon capital management llc	5.1%	1,392,402	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 07, 2023	blackrock inc.	5.9%	1,638,326	SC 13G/A
Feb 02, 2023	arkin moshe	4.98%	1,371,074	SC 13G/A
Nov 07, 2022	orbimed advisors llc	4.6%	1,268,734	SC 13D/A

Recent SEC filings of Keros Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
Apr 17, 2024	ARS	ARS
Apr 17, 2024	DEF 14A	DEF 14A
Apr 17, 2024	DEFA14A	DEFA14A
Mar 14, 2024	8-K	Current Report
Mar 06, 2024	8-K	Current Report
Mar 05, 2024	8-K	Current Report
Mar 05, 2024	8-K	Current Report
Feb 29, 2024	S-8	Employee Benefits Plan
Feb 28, 2024	10-K	Annual Report
Feb 28, 2024	8-K	Current Report

Peers (Alternatives to Keros Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	42.6B	6.8B	4.75%	-16.01%	-9.05	6.23	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.6B	1.8B	-1.40%	-26.02%	-42.16	10.15	76.23%	61.08%
BMRN	15.4B	2.5B	-5.97%	-14.48%	74.78	6.22	13.74%	186.89%
INCY	11.8B	3.7B	-7.74%	-29.36%	19.75	3.19	8.87%	75.42%
MID-CAP
APLS	5.8B	396.6M	-18.63%	-42.67%	-10.91	14.55	425.83%	18.94%
BBIO	4.5B	-	-17.63%	75.41%	-6.86	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-7.66%	3.02%	-14.59	12.9	440.80%	-27.84%
ARWR	2.9B	240.7M	-19.13%	-34.68%	-9.65	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-7.52%	-19.83%	-45.97	3.88	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.45%	-4.33%	25.14	4.51	85.90%	-14.05%
NVAX	600.4M	983.7M	-10.25%	-44.07%	-1.1	0.61	-50.36%	17.16%
CRBP	374.0M	881.7K	-9.17%	305.92%	-8.38	466.16	-77.61%	-5.33%
INO	268.8M	4.9M	-17.15%	24.46%	-1.99	55.23	-54.97%	51.71%
IBIO	5.8M	2.1M	-59.11%	53.70%	-0.21	2.14	-13.45%	66.37%

Keros Therapeutics Inc News

Latest updates

Keros Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2022Q4	2022Q3	2022Q2	2021Q4	2021Q3	2021Q2	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-	-	-	3,705,000	3,376,000	3,157,000	2,938,000	2,719,000	2,500,000	2,500,000	2,500,000	2,500,000	-
Operating Expenses	45.8%	46,598,000	31,960,000	27,976,000	30,728,000	24,866,000	20,197,000	15,641,000	5,228,000	4,826,000	5,151,000	5,358,000	-
S&GA Expenses	28.4%	9,105,000	7,093,000	6,937,000	7,447,000	6,033,000	5,365,000	5,658,000	1,067,000	972,000	654,000	491,000	-
R&D Expenses	50.8%	37,493,000	24,867,000	21,039,000	23,281,000	18,833,000	14,832,000	9,983,000	4,161,000	3,854,000	4,497,000	4,867,000	-
EBITDA Margin	-194.6%	-43.28	-14.69	-7.67	-5.60	-2.80	-6.21	-5.38	-	-	-	-	-
Interest Expenses	-	-	-	-	-	1,000	1,000	1,000	-	3,000	2,000	2,000	-
Income Taxes	-	-	-	-	-	1,999,000	-38,000	-	-	-	-	-	-
Earnings Before Taxes	100.0%	-	-29,718,000	-23,509,000	-27,266,000	-4,941,000	-20,335,000	-15,622,000	-2,751,000	-3,549,000	-2,853,000	-3,183,000	-
EBT Margin	-195.0%	-43.62	-14.78	-7.73	-5.65	-2.82	-6.25	-5.42	-	-	-	-	-
Net Income	-35.4%	-40,243,000	-29,718,000	-23,509,000	-27,266,000	-6,940,000	-20,297,000	-15,622,000	-2,751,000	-3,549,000	-2,853,000	-3,183,000	-
Net Income Margin	-331.2%	-63.75	-14.78	-7.92	-5.79	-2.92	-6.25	-5.42	-	-	-	-	-
Free Cashflow	-19.3%	-26,000,000	-21,794,000	-24,778,000	-23,157,000	-19,724,000	-14,586,000	-18,147,000	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																		(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2018Q4
Assets	13.4%	370	326	356	384	307	253	227	235	255	230	243	258	269	138	150	61.00	11.00	27.00
Current Assets	14.1%	347	304	334	362	286	246	222	231	251	226	241	256	268	136	149	59.00	9.00	26.00
Cash Equivalents	15.0%	331	288	322	351	279	239	216	229	230	221	237	255	266	134	145	55.00	7.00	23.00
Net PPE	23.1%	4.00	3.00	3.00	3.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Liabilities	24.4%	38.00	30.00	30.00	29.00	29.00	12.00	15.00	12.00	12.00	11.00	8.00	9.00	8.00	7.00	9.00	10.00	10.00	15.00
Current Liabilities	45.9%	24.00	17.00	16.00	15.00	17.00	12.00	15.00	12.00	12.00	11.00	8.00	9.00	7.00	7.00	8.00	9.00	4.00	11.00
Shareholder's Equity	12.3%	332	296	326	355	277	241	211	223	243	218	236	248	262	131	141	-	-	-
Retained Earnings	-11.8%	-381	-341	-301	-264	-228	-198	-175	-147	-123	-116	-96.52	-80.90	-65.01	-54.33	-42.30	-31.54	-19.65	-7.31
Additional Paid-In Capital	12.0%	714	637	628	619	506	440	386	371	367	335	332	329	327	185	184	7.00	0.00	0.00
Shares Outstanding	7.3%	32.00	30.00	30.00	30.00	28.00	25.00	24.00	24.00	23.00	23.00	23.00	23.00	-	-	-	-	-	-
Float	-	-	-	905	-	-	-	471	-	-	-	657	-	-	-	386	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	25.1%	-25,459	-33,982	-30,832	-34,235	-21,443	-24,602	-22,590	-1,427	-19,565	-14,441	-17,637	-10,505	-7,991	-10,856	-9,927	-8,120	-5,498	-2,955	-5,032	-2,513	-
Share Based Compensation	-15.9%	7,324	8,711	7,041	5,687	4,746	4,754	4,794	4,388	3,295	3,084	2,849	2,494	1,522	1,424	1,139	12.00	18.00	17.00	13.00	11.00	-
Cashflow From Investing	1.6%	-541	-550	-311	-1,062	-351	-176	-567	-147	-159	-145	-510	-210	-60.00	-30.00	-28.00	-176	-18.00	-82.00	-171	-	-
Cashflow From Financing	24285.2%	69,254	284	1,740	107,678	61,416	48,583	10,192	118	28,416	35.00	57.00	42.00	140,117	9.00	100,124	55,794	4.00	6.00	4.00	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

KROS Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
REVENUE:
Total revenue	$ 151	$ 0	$ 20,100
OPERATING EXPENSES:
Research and development	(135,258)	(87,265)	(55,143)
General and administrative	(34,834)	(27,525)	(21,330)
Total operating expenses	(170,092)	(114,790)	(76,473)
LOSS FROM OPERATIONS	(169,941)	(114,790)	(56,373)
OTHER INCOME (EXPENSE), NET:
Interest expense, net	0	(1)	(4)
Research and development incentive income	2,400	7,081	0
Dividend income	14,755	3,644	27
Other income (expense), net	(206)	(613)	(383)
Total other income (expense), net	16,949	10,111	(360)
Loss before income taxes	(152,992)	(104,679)	(56,733)
Income tax provision	0	0	(2,011)
Net loss	(152,992)	(104,679)	(58,744)
Net loss attributable to common stockholders - basic	(152,992)	(104,679)	(58,744)
Net loss attributable to common stockholders - diluted	$ (152,992)	$ (104,679)	$ (58,744)
Net loss per share attributable to common stockholders - basic (in dollars per share)	$ (5.20)	$ (4.15)	$ (2.52)
Net loss per share attributable to common stockholders - diluted (in dollars per share)	$ (5.20)	$ (4.15)	$ (2.52)
Weighted-average common stock outstanding - basic (in shares)	29,447,119	25,241,030	23,333,914
Weighted-average common stock outstanding - diluted (in shares)	29,447,119	25,241,030	23,333,914
Service and other revenue
REVENUE:
Total revenue	$ 151	$ 0	$ 0
License revenue
REVENUE:
Total revenue	$ 0	$ 0	$ 20,100

KROS Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
CURRENT ASSETS:
Cash and cash equivalents	$ 331,147	$ 279,048
Accounts receivable	143	0
Prepaid expenses and other current assets	16,003	6,719
Total current assets	347,293	285,767
Operating lease right-of-use assets	15,334	15,548
Property and equipment, net	4,134	2,021
Restricted cash	1,212	1,327
Other long term assets	2,052	2,118
TOTAL ASSETS	370,025	306,781
CURRENT LIABILITIES:
Accounts payable	5,450	3,339
Current portion of operating lease liabilities	1,005	455
Accrued expenses and other current liabilities	17,918	12,753
Total current liabilities	24,373	16,547
Operating lease liabilities, net of current portion	13,439	12,811
Total liabilities	37,812	29,358
COMMITMENTS AND CONTINGENCIES (Note 11)
STOCKHOLDERS’ EQUITY:
Preferred stock, par value of $0.0001 per share; 10,000,000 shares authorized as of December 31, 2023 and December 31, 2022, respectively; no shares issued and outstanding	0	0
Common stock, par value of $0.0001 per share; 200,000,000 shares authorized as of December 31, 2023 and December 31, 2022; 31,841,084 and 27,543,453 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively	3	2
Additional paid-in capital	713,636	505,855
Accumulated deficit	(381,426)	(228,434)
Total stockholders’ equity	332,213	277,423
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 370,025	$ 306,781

About Keros Therapeutics Inc

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical need in the United States. The company's lead protein therapeutic product candidate KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-047, a small molecule product candidate that is in Phase II clinical trials for the treatment of functional iron deficiency; and KER-012, which is in Phase II clinical trials to treat pulmonary arterial hypertension and cardiovascular disorders. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

CEO	Dr. Jasbir S. Seehra Ph.D.
WEBSITE	kerostx.com
INDUSTRY	Biotechnology
EMPLOYEES	121

Keros Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Keros Therapeutics Inc? What does KROS stand for in stocks?

KROS is the stock ticker symbol of Keros Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Keros Therapeutics Inc (KROS)?

As of Mon Apr 29 2024, market cap of Keros Therapeutics Inc is 2.11 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of KROS stock?

You can check KROS's fair value in chart for subscribers.

What is the fair value of KROS stock?

You can check KROS's fair value in chart for subscribers. The fair value of Keros Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Keros Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for KROS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Keros Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether KROS is over valued or under valued. Whether Keros Therapeutics Inc is cheap or expensive depends on the assumptions which impact Keros Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for KROS.

What is Keros Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 29 2024, KROS's PE ratio (Price to Earnings) is -13.79 and Price to Sales (PS) ratio is 1.01 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. KROS PE ratio will change depending on the future growth rate expectations of investors.